Literature DB >> 27729654

Therapy: No benefit for adjuvant capecitabine plus bevacizumab in colorectal cancer.

Iain Dickson.   

Abstract

Entities:  

Year:  2016        PMID： 27729654     DOI： 10.1038/nrgastro.2016.173

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  1 in total

1.  Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial.

Authors:  Rachel S Kerr; Sharon Love; Eva Segelov; Elaine Johnstone; Beverly Falcon; Peter Hewett; Andrew Weaver; David Church; Claire Scudder; Sarah Pearson; Patrick Julier; Francesco Pezzella; Ian Tomlinson; Enric Domingo; David J Kerr
Journal:  Lancet Oncol       Date:  2016-09-19       Impact factor: 41.316
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.